Log in to search using one of your social media accounts:

This page shows you the latest items in this publication.

ICYMI: What the experts are saying about importation
Voices throughout the U.S. and Canadian health care systems have raised concerns about proposed large-scale drug importation schemes. Former government officials, pharmacy groups and experts have called attention to the potential dangers associated with these importation schemes, as well as the lack of cost savings for American patients. Here ’s a look at what they’re saying: (Source: The Catalyst)
Source: The Catalyst - March 23, 2017 Category: Pharmaceuticals Tags: Imported Drugs Source Type: news

Guest Post: The importance of a modern FDA in drug discovery
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to share a blog post that was written by Jim Robinson, President, Astellas Americas, and originally published onThe Astellas Way. (Source: The Catalyst)
Source: The Catalyst - March 22, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: FDA PhRMA Member Company PDUFA FDA Modernization Source Type: news

Medicare Monday: Billing code basics for biologics in Part B
We ’ve explored the Centers for Medicare& Medicaid Services ’ (CMS) flawed policy for reimbursing biologic and biosimilar productsbefore. Today, we ’re exploring how proposals from MedPAC would build on this flawed approach and put access to these important medicines at risk. (Source: The Catalyst)
Source: The Catalyst - March 20, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Biologics and Biosimilars Part B Source Type: news

How drug importation schemes could increase U.S. law enforcement burdens
In recent weeks, we ’ve explored some of thedangers of importation for patients and how medicines purchased online can be fake. But what would importation schemes mean for U.S. law enforcement? (Source: The Catalyst)
Source: The Catalyst - March 16, 2017 Category: Pharmaceuticals Tags: Safety imported Drugs Source Type: news

Medicare Monday: A closer look at Part B spending
Earlier this month,MedPAC discussed Part B drug spending growth but neglected to put this information in the context of overall program spending. Spending on Part B medicines continues to be a small and stable share of spending. Here are the facts. (Source: The Catalyst)
Source: The Catalyst - March 13, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
Modernizing certain laws and regulations to support the move to value-drive health care is an important step in moving our health care system forward. As part of PhRMA ’s proactive policy solutions, we’verecommended modernizing of the Anti-Kickback Statute to support expanded value-based contracting between biopharmaceutical companies and private payers or health care providers.  (Source: The Catalyst)
Source: The Catalyst - March 6, 2017 Category: Pharmaceuticals Tags: Value-Driven Health Care Policy Solutions Source Type: news

Medicare Monday: New study further confirms increased use of generics after Part D
OnMedicare Monday, we ’ve talked a lot about how things have changed since 2006 and the implementation of Part D. We’ve looked at howPart D costs less than originally projected, howpremiums have remained steady and howcompetition has worked to keep costs low. (Source: The Catalyst)
Source: The Catalyst - March 6, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

Guest Post: Room for optimism in ALS research
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. (Source: The Catalyst)
Source: The Catalyst - March 3, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

Guest Post: Debra of America on Epidermolysis Bullosa
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Brett Kopelan, executive director for Debra of America. (Source: The Catalyst)
Source: The Catalyst - March 3, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

Guest Contributor: Debra of America on Epidermolysis Bullosa
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Brett Kopelan, executive director for Debra of America. (Source: The Catalyst)
Source: The Catalyst - March 3, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

Guest Post: A Cure for Ellie on Leukodystrophy-LBSL
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Beth McGinn, operator of “A Cure for Ellie,” a non-profit foundation named for her eight-year old daughter. A Cure for Ellie supports cut...
Source: The Catalyst - March 2, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

Case Study: How one online pharmacy knowingly endangered U.S. consumers
We recently looked atwhat actually happens when a patient orders a medicine through an online Canadian pharmacy and how the product delivered may not be what the patient ordered. Today, we ’re taking it one step further and looking at a real example of one online pharmacy that was caught selling counterfeit medicines to U.S. consumers. (Source: The Catalyst)
Source: The Catalyst - March 2, 2017 Category: Pharmaceuticals Tags: Safety Counterfeit Drugs imported Drugs Source Type: news

Guest Post: Epilepsy Foundation on rare diseases
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Angela Ostrom, chief legal officer& vice President public policy for the Epilepsy Foundation. (Source: The Catalyst)
Source: The Catalyst - March 1, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

How innovative medicines are benefiting countries across the globe
It is important to look at costs across health care systems to fully understand how life-changing medicines are providing a more sustainable path forward. Across the globe, medicines are allowing patients to lead healthier and more productive lives while also yielding significant cost savings. (Source: The Catalyst)
Source: The Catalyst - March 1, 2017 Category: Pharmaceuticals Tags: drug cost Source Type: news

Why drug importation threatens patient safety
Counterfeit drug manufacturing and trafficking is a multi-billion dollar business. Legislative proposals to allow importation of potentially counterfeit and substandard drugs into the United States are unsafe and put American patients at risk. This is because the U.S. government cannot guarantee that medicines entering the country via importation schemes will meet our strict safety standards. Here ’s a closer look at why these proposals put patient safety at risk: (Source: The Catalyst)
Source: The Catalyst - February 28, 2017 Category: Pharmaceuticals Tags: Safety Counterfeit Drugs imported Drugs Source Type: news

Rare Disease Day: Accelerating innovation for patients in need
As we celebrate Rare Disease Day, it is important to not only reflect on how far we have come in tackling these devastating and complex conditions, but how much unmet medical remains. While more than 7,000 rare diseases have been identified, only 5 percent have treatments. As the majority of these diseases are life threatening, these facts underscore the need for new medicines. (Source: The Catalyst)
Source: The Catalyst - February 28, 2017 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: Rare Diseases Source Type: news

Medicare Monday: There ’s an agency called MedPAC?
Now that we ’ve learned more aboutIPAB andCMMI, there ’s one more agency on our list to read up on this month – the Medicare Payment Advisory Commission (MedPAC). (Source: The Catalyst)
Source: The Catalyst - February 27, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Source Type: news

Fact Check Friday: The truth about drug importation and patient safety
This week on Fact Check Friday, we ’re discussing the truth about proposals to allow the importation of medicines from other countries and what these proposals mean for patients.MYTH:Importation is safe.FACT:Importation is dangerous for U.S. patients. (Source: The Catalyst)
Source: The Catalyst - February 24, 2017 Category: Pharmaceuticals Tags: Safety Importation Source Type: news

How do multiple sclerosis patients define value?
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value,Real Endpoints conducted research that found significant variability in treatment preferences among MS patients, as well as a difference in how patients define value in MS therapies compared to payers and physicians. (Source: The Catalyst)
Source: The Catalyst - February 24, 2017 Category: Pharmaceuticals Tags: Patients chronic disease Multiple Sclerosis Value-Driven Health Care Policy Solutions Source Type: news

PPA: 2016 in review
More than a decade has passed since the Partnership for Prescription Assistance (PPA) launched. In this time, PPA has helped nearly 10 million patients through its free and confidential program, but last year was a particularly special year for the program. (Source: The Catalyst)
Source: The Catalyst - February 23, 2017 Category: Pharmaceuticals Tags: PPA PPARX Source Type: news

ICYMI: New era of medicine initiative kicks off in Boston
It ’s no secret that Boston, Massachusetts is home to many of the most groundbreaking advancements in medical discovery. That’s why yesterday, PhRMA sponsored its first national health care dialogue series focusing on the new era of medicine. The event, convened byThe Atlantic, titled, “Through the Microscope: Examining Modern Medicine, ” explored the transformation of patient care and the science that has revolutionized medical breakthroughs, new treatments and technologies, as well as the investments needed for future innovation. (Source: The Catalyst)
Source: The Catalyst - February 22, 2017 Category: Pharmaceuticals Tags: Innovation Patients Source Type: news

Exploring the new era of medicine
We are in a new era of medicine where innovations are transforming our ability to attack the cause of disease, not just the symptoms. Where treatment decisions are increasingly focused on the needs of the individual patient and where science fiction is now becoming a reality. (Source: The Catalyst)
Source: The Catalyst - February 21, 2017 Category: Pharmaceuticals Authors: Bill Chin, M.D. Tags: Innovation member companies Drug Development Source Type: news

Medicare Monday: Have you heard of CMMI?
(Source: The Catalyst)
Source: The Catalyst - February 20, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday CMMI Source Type: news

ICYMI – 3 new reports show dramatic slowdown in medicine spending growth
Newly released government actuary and pharmacy benefit manager data confirm previous projections of a significant decline in medicine spending growth. After accounting for discounts and rebates, medicine spending growth in 2016 dipped into the low single digits, with growth rates between 2 and 5 percent. (Source: The Catalyst)
Source: The Catalyst - February 17, 2017 Category: Pharmaceuticals Tags: drug cost Source Type: news

What you don ’t know about importation from Canada
Proposals to allow the importation of prescription medicines from Canada ignore the dangerous threat to patients of counterfeit and adulterated medicines. What actually happens when a patient orders a medicine through an online Canadian pharmacy may not be what you think. Counterfeit and adulterated medicines may contain paint, drywall or other harmful ingredients, be handled incorrectly or, in some cases, contain no active ingredients at all. Often these medicines look so similar patients cannot tell the difference. This infographic explores the realities of importation, comparing what you think happens in Canada with wha...
Source: The Catalyst - February 17, 2017 Category: Pharmaceuticals Tags: Safety imported Drugs Source Type: news

Biopharmaceutical industry ’s success reducing disparities for African Americans
February is Black History Month, and here at PhRMA, we continue our decades-long commitment to reducing disparities in health care for minorities through developing and helping communities access innovative medicines and cures. (Source: The Catalyst)
Source: The Catalyst - February 16, 2017 Category: Pharmaceuticals Authors: Myisha Gatson Tags: Access Patients HIV/AIDS heart disease Source Type: news

Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
As a health care company with the mission of bringing forward transformational solutions for patients and consumers, innovative scientific advances are the essence of our success. We believe that a great idea can come from anywhere, and we are proud to fuel and support innovators all over the world.One way in which Johnson& Johnson supports and celebrates the role of scientists in advancing human health is theDr. Paul Janssen Award for Biomedical Research. This award honors the legacy of Dr. Paul Janssen, a gifted scientist and luminary in the pharmaceutical industry. Anyone who works in this industry knows what a feat...
Source: The Catalyst - February 15, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: member companies Source Type: news

Watch: Biomarkers in drug development with Dr. Bernie Zeiher
Biomarkers arepowerful tools which are used by medical professionals in many ways, including in the diagnosis of disease, monitoring how a disease is progressing and, if a treatment is given, how the body is responding. Biomarkers may also help biopharmaceutical researchers determine which medicines may be most effective in certain patients. In a new series of videos Dr. Bernie Zeiher, president of development at Astellas Pharma, discusses how scientists are using biomarkers to create more precise, personalized treatment approaches for patients. (Source: The Catalyst)
Source: The Catalyst - February 14, 2017 Category: Pharmaceuticals Tags: member companies Drug Development Clinical Trials biomarkers Source Type: news

Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
The manufacturing and trafficking of counterfeit drugs is not just a U.S. concern but a growing threat globally. Governments around the world are working together to try to prevent these fake products from reaching and harming patients. While the U.S. market is the most secure with a closed supply chain, there remains the threat of counterfeit and adulterated drugs reaching U.S. patients. This risk increases dramatically if medicines are imported from and travel through other countries before reaching the United States because there would be no way to ensure the safety and efficacy of those products. (Source: The Catalyst)
Source: The Catalyst - February 13, 2017 Category: Pharmaceuticals Tags: Safety imported Drugs Hepatitis C Source Type: news

Medicare Monday: What is IPAB,  and why is it bad for patients?
In 2017,the Independent Payment Advisory Board (IPAB)couldfinally go into effectand come between patientsand their health care providers. This week, we ’re looking into this dangerous body.   (Source: The Catalyst)
Source: The Catalyst - February 13, 2017 Category: Pharmaceuticals Tags: Access Medicare Medicare Monday IPAB Source Type: news

PhRMA Urges USTR to Protect American Innovators Abroad
Yesterday, PhRMA submittedcomments for the2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property and market access barriers in 18 countries that harm biopharmaceutical innovators in the United States and the patients they serve around the world. (Source: The Catalyst)
Source: The Catalyst - February 10, 2017 Category: Pharmaceuticals Tags: Patents IP trade Source Type: news

340B Spotlight: Audit findings show importance of increased oversight of 340B program
The 340B Drug Discount Program is an important component of the health care safety net, providing help to vulnerable or uninsured patients. However, with great power comes great responsibility, and ensuring the program is sustainable and directly benefits vulnerable or uninsured patients, while certifying that program requirements are being met, is crucial. (Source: The Catalyst)
Source: The Catalyst - February 9, 2017 Category: Pharmaceuticals Tags: 340B hospitals 340B Spotlight Source Type: news

PhRMA CEO talks White House meeting, innovation & jobs with POLITICO ’s Pulse Check
Following the biopharmaceutical industry ’s recentmeeting with President Donald J. Trump, PhRMA president and CEO Stephen J. Ubl joined Dan Diamond on POLITICO ’sPulse Check podcast to discuss the future of innovation in health care and the industry ’s new national advertising and public affairs campaign:GOBOLDLY. The campaign focuses on the new era of medicine, public health and ways we can evolve our private payment and reimbursement system to be as innovative as the medicines our companies produce. (Source: The Catalyst)
Source: The Catalyst - February 9, 2017 Category: Pharmaceuticals Tags: Value-Driven Health Care Source Type: news

VIDEO: PhRMA CEO joins Fox Business anchor Neil Cavuto to discuss personal connection to value of innovation and White House meeting
PhRMA president and CEO Stephen J. Ubl recently spoke withFOX Business anchor Neil Cavuto on hispersonal connection to the value of medical technology with his son ’s type 1 diabetes diagnosis, the industry’s meeting with President Donald J. Trump and access and affordability challenges for patients. (Source: The Catalyst)
Source: The Catalyst - February 6, 2017 Category: Pharmaceuticals Tags: Value-Driven Health Care Source Type: news

Medicare Monday: Did you know … ?
OnMedicare Monday, we talk a lot about Medicare Part D and how it works, but here are five things you might not know about the program. (Source: The Catalyst)
Source: The Catalyst - February 6, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
Today, as part of our new advertising and public affairs initiative, GOBOLDLY, we are excited to announce the premier of our newest TV advertisement,Cells, which highlights innovative immunotherapy treatments by America ’s biopharmaceutical companies. (Source: The Catalyst)
Source: The Catalyst - February 5, 2017 Category: Pharmaceuticals Tags: cancer Source Type: news

VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney ’s Maggie Lake
PhRMA president and CEO Stephen J. Ubl joined Maggie Lake onCNNMoney this week to talk about the industry ’s new national campaign,GOBOLDLY, andmeeting with President Donald J. Trump. He also discussed with Maggie how the industry plans to advance private market solutions to achieve better health, lower costs through the newly announced initiative,The Value Collaborative. (Source: The Catalyst)
Source: The Catalyst - February 3, 2017 Category: Pharmaceuticals Tags: Value Value-Driven Health Care Source Type: news

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch ofGOBOLDLY, our new national, multi-year initiative brings those bold, life-changing medical discoveries to the forefront. Yet, at the core of this effort is also our responsibility to make our health care system more responsive to the needs of patients.  (Source: The Catalyst)
Source: The Catalyst - January 31, 2017 Category: Pharmaceuticals Tags: drug cost Value-Driven Health Care Policy Solutions Source Type: news

PhRMA CEO Statement Following Meeting With President Trump
This morning, we had a positive, productive meeting with President Trump, Vice President Pence and House Energy and Commerce Chairman Greg Walden, (R-Ore.). We talked about how we can work together to improve American competitiveness around the world, create more jobs here at home and enhance the U.S. biopharmaceutical industry that continues to lead the world in the development of lifesaving treatments and cures. (Source: The Catalyst)
Source: The Catalyst - January 31, 2017 Category: Pharmaceuticals Source Type: news

Medicare Monday: How Part D helps patients with heart disease live longer, healthier lives
Wednesday kicks off American Heart Month, so this week we ’re looking at heart health and how important it is for patients to have access to needed medicines for heart disease and stroke. This is especially true for older Americans. According to theAmerican Heart Association, nearly 7 in 10 Americans age 60 to 79 have cardiovascular disease. (Source: The Catalyst)
Source: The Catalyst - January 30, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday heart disease Source Type: news

Ask About Adherence: Q & A on appointment-based medication synchronization
Ask About Adherence is a blog series featuring Q&A ’s with experts and new medication adherence resources. In this post, we spoke with David A. Holdford, Ph.D., Professor, Director of International Programs, Department of Pharmacotherapy and Outcomes Science at the Virginia Commonwealth University School of Pharmacy in Richmond, Virginia.Stay tuned for the next blog and be sure to share your thoughts in the comments section below. (Source: The Catalyst)
Source: The Catalyst - January 27, 2017 Category: Pharmaceuticals Tags: Ask About Adherence Source Type: news

VIDEO: PhRMA CEO joins CNBC ’s Squawk on the Street to discuss industry campaign #GOBOLDLY
PhRMA President and CEO Stephen J. Ubl spoke with the anchors of CNBC ’s Squawk on the Street about the biopharmaceutical industry’s new national, multi-year advertising and public affairs campaign: #GOBOLDLY. The campaign heralds the new era of medicine and will convene a national dialogue on policy solutions to sustain bold advancements. (Source: The Catalyst)
Source: The Catalyst - January 24, 2017 Category: Pharmaceuticals Source Type: news

Medicare Monday: How Medicare helps beneficiaries access needed medicines
Throughout 2016, we looked at how different groups of beneficiaries – from seniors to minority communities to individuals with lower-incomes – rely on Medicare to access their needed prescription medications. (Source: The Catalyst)
Source: The Catalyst - January 23, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Part B Extra Help Program case studies Source Type: news

Medicare Monday: A closer look at Medicare Part B
We took a deeper dive on Medicare Part D last week, so today we ’re switching gears and talking about Medicare Part B. (Source: The Catalyst)
Source: The Catalyst - January 16, 2017 Category: Pharmaceuticals Authors: Kelsey Lang Tags: Medicare Medicare Monday Part B Source Type: news

The 20-year journey yielding a new weapon against cancer
Developing new medicines is a long, complex process. On average, it takesat least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient ’s treatment regimen. In some cases, however, it can take even longer. (Source: The Catalyst)
Source: The Catalyst - January 10, 2017 Category: Pharmaceuticals Tags: cancer PhRMA Leukemia Source Type: news

Significant progress fighting cancer: Death rate has dropped 25 percent
Cancers have long been one of the most devastating and complex disease areas facing patients. But thanks in part to innovative advancements in treatments and early detection, thecancer death rate in the United States has dropped 25 percent over the last two decades.According to estimates in theCancer Statistics 2017report, this consistent decline over 23 years has resulted in 2.1 million fewer cancer deaths during this period than if death rates had remained at their peak. (Source: The Catalyst)
Source: The Catalyst - January 9, 2017 Category: Pharmaceuticals Tags: Medicines in Development Innovation new medicines Personalized Medicine cancer Source Type: news

Medicare Monday: A refresh on private negotiation in Part D
Last week, we highlighted a number of Medicare resources – from how to learn more about which medicines are covered in Part B to how Part D has been a success since its implementation. And this week, we thought we’d dive into the structure of Part D, specifically the private negotiation that occurs within the program and why interfering with this nego tiation could negatively impact beneficiaries. (Source: The Catalyst)
Source: The Catalyst - January 9, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

3 things to know about 2016 drug approvals
In 2016, the U.S. Food and Drug Administration ’s (FDA) Center for Drug Evaluation and Research (CDER)approved 22 new medicines to treat a broad range of illnesses for patients in need. These much-needed new treatments include medicines for multiple sclerosis, chronic lymphocytic leukemia, ovarian and bladder cancer and the very rare spinal muscular atrophy (SMA). (Source: The Catalyst)
Source: The Catalyst - January 6, 2017 Category: Pharmaceuticals Tags: Medicines in Development PhRMA Fact Check FDA Modernization Source Type: news

Medicare Monday: Kicking off 2017 with Medicare resources
Happy New Year,#MedicareMonday readers! (Source: The Catalyst)
Source: The Catalyst - January 2, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Part B Extra Help Program Source Type: news

Medicare Monday: Looking back at the success of Part D in its first 10 years
As 2016 comes to a close this week, Medicare Part D wraps up its first decade – and it’s been quite a busy decade. Today, more than 40 million people, including seniors and people living with disabilities, rely on Medicare Part D to access their needed prescriptions.The program has been a success for these beneficiaries, as well as taxpayers. In fact, multiple studies have found about 90 percent or more of beneficiaries are satisfied with their Part D coverage. (Source: The Catalyst)
Source: The Catalyst - December 26, 2016 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news